Thrombolytic therapies with plasminogen activators (t-PA, SK and UK) have high potential in treating thrombosis, facilitating the use of plasminogen activators in medicine today, but their high prices and side effects limit their wide application. This evidence concerns the gene PLAT and Venous thrombosis.